Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib in ALK/ROS1+ tumors (SIGNATURE)
NCT02186821Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2014
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ceritinib in solid tumor and hematologic malignancy, sponsored by Novartis. Primary endpoints: Overall Response Rate at 16 weeks and Clinical Benefit Rate at 16 weeks. Started Sep 2014; status: terminated.
02
Drugs
ceritinib
03
Conditions
solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT02186821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02186821.